Healthcare [ 7/13 ] | Health Information Services [ 90/163 ]
NASDAQ | Common Stock
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally.
It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions.
In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench.
Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data.
It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries.
Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 24 | 0.10 Decreased by -16.67% | 0.10 |
| Feb 29, 24 | 0.09 Decreased by -43.75% | 0.11 Decreased by -18.18% |
| Nov 8, 23 | 0.11 Increased by +10.00% | 0.11 |
| Aug 9, 23 | 0.12 Increased by +33.33% | 0.13 Decreased by -7.69% |
| May 8, 23 | 0.12 Increased by +9.09% | 0.12 |
| Mar 1, 23 | 0.16 Increased by +1.50 K% | 0.13 Increased by +23.08% |
| Nov 7, 22 | 0.10 Increased by +42.86% | 0.10 |
| Aug 9, 22 | 0.09 Increased by +200.00% | 0.11 Decreased by -18.18% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 96.65 M Increased by +7.04% | -4.68 M Decreased by -444.85% | Decreased by -4.85% Decreased by -422.18% |
| Dec 31, 23 | 88.01 M Increased by +1.59% | -12.46 M Decreased by -235.78% | Decreased by -14.15% Decreased by -233.65% |
| Sep 30, 23 | 85.58 M Increased by +1.03% | -48.97 M Decreased by -1.34 K% | Decreased by -57.22% Decreased by -1.33 K% |
| Jun 30, 23 | 90.45 M Increased by +9.29% | 4.71 M Increased by +898.98% | Increased by +5.20% Increased by +831.05% |
| Mar 31, 23 | 90.30 M Increased by +10.73% | 1.36 M Decreased by -38.55% | Increased by +1.50% Decreased by -44.51% |
| Dec 31, 22 | 86.63 M Increased by +14.98% | 9.17 M Increased by +194.59% | Increased by +10.59% Increased by +182.26% |
| Sep 30, 22 | 84.70 M Increased by +14.55% | 3.94 M Increased by +323.38% | Increased by +4.65% Increased by +295.02% |
| Jun 30, 22 | 82.76 M Increased by +18.07% | -589.00 K Increased by +79.38% | Decreased by -0.71% Increased by +82.54% |